NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring preclinical data from its GD2 SADA construct will be presented at the AACR Annual Meeting 2022, which takes place in New Orleans, Louisiana from April 8-13, 2022.
Pre-clinical models have shown that the tetramerizing function of the SADA domain appears to be important to the binding activity and anti-tumor effect of GD2 SADA. Data confirms that the SADA domain seems to increase tumor antigen binding, uptake and persistence in tumor tissue, and markedly improves anti-tumor responses in pre-clinical models.
The SADA technology was licensed by the Company from Memorial Sloan Kettering (“MSK”) and the Massachusetts Institute of Technology. Researchers at MSK developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs. MSK has institutional financial interests in the technology.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic cancer products. In addition to conventional antibodies, the Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s broad and advanced product pipeline includes one FDA-approved product, DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and one product candidate at the registration-stage, omburtamab, which targets tumors that express B7-H3.